BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2014

View Archived Issues

Novel single nucleotide polymorphisms associated with bipolar disorder

Read More

NeurOp receives further NIH funding to develop cerebral ischemia candidate

Read More

Clinical data demonstrate the feasibility of roniciclib in SCLC and ovarian cancer

Read More

CellCollector may improve circulating tumor cell collection for breast cancer monitoring

Read More

Novel potent dual kinase EGFR inhibitor synthesized at Innova Pharmaceuticals

Read More

Lexicon Pharmaceuticals reports topline data for LX-4211 in type 1 diabetes

Read More

Cellceutix antibiotic shows activity against drug-resistant K. pneumoniae

Read More

Agios Pharmaceuticals begins phase I study of AG-348 in healthy volunteers

Read More

Alimera Sciences confirms new FDA action date for Iluvien

Read More

Novel sequencing method developed for the GBA gene

Read More

Scripps Research Institute launches new drug discovery initiative

Read More

Bristol-Myers Squibb patents new prodrugs of Notch signaling inhibitors

Read More

Midwestern University discloses novel FTO modulators

Read More

Covagen discloses novel IL-17A bispecific fusion proteins

Read More

NeoStem to acquire California Stem Cell and initiate phase III melanoma trial

Read More

VPM-1002 shows favorable preclinical and early clinical profile for the treatment of bladder cancer

Read More

Aapa BV discloses new SERT inhibitors and 5-HT2C receptor antagonists

Read More

Peginterferon alfa-2b follow-on biologic is noninferior in phase II/III trial

Read More

Ziarco Pharma presents novel SYK kinase inhibitors

Read More

FDA approves clinical trial initiation for Vivolux's mitochondria-targeting agent

Read More

DesignMedix receives NIH grant for antimalarial drug

Read More

FDA accepts NDA filing for Boehringer Ingelheim/Lilly diabetes combination tablet

Read More

Bristol-Myers Squibb files NDA for HIV-1 fixed-dose combination tablet

Read More

Grastek immunotherapy for grass pollen-induced allergic rhinitis approved by FDA

Read More

Phase III Livatag study recommended to continue by safety board

Read More

Critical Pharmaceuticals and University of Nottingham initiate first-in-human trial in osteoporosis

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing